Adverse events and dose modifications of tyrosine kinase inhibitors in chronic myelogenous leukemia

The prognosis of chronic myelogenous leukemia (CML-CP) in chronic phase has improved dramatically since the introduction of imatinib. In addition to imatinib, second- and third-generation tyrosine kinase inhibitors (TKIs) and a novel allosteric inhibitor, asciminib, are now available. During long-te...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoshifuji, Kota, Sasaki, Koji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9583346/
https://www.ncbi.nlm.nih.gov/pubmed/36276124
http://dx.doi.org/10.3389/fonc.2022.1021662

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9583346/
https://www.ncbi.nlm.nih.gov/pubmed/36276124
http://dx.doi.org/10.3389/fonc.2022.1021662

Ejemplares similares